Results of ACCURATE study show advantage of Axium Neurostimulator System in pain relief- St Jude Medical
St. Jude Medical has announced long term data from the ACCURATE study has confirmed dorsal root ganglion (DRG) stimulation with the St. Jude Medical Axium Neurostimulator System provides sustained and superior pain relief over traditional spinal cord stimulation (SCS) in patients with complex regional pain syndrome (CRPS) or peripheral causalgia. In addition, patients receiving DRG stimulation reported better therapeutic targeting and a reduction in paresthesia (the tingling feeling common to traditional SCS) compared to traditional tonic SCS.
Results show sustained and superior pain relief: after 12 months, the ACCURATE study demonstrated a statistically significantly number of patients receiving DRG stimulation achieved meaningful pain relief and greater treatment success when compared to patients receiving traditional SCS (74.2 percent vs. 53 percent). The study also shows improved therapeutic targeting: Nearly all patients receiving DRG stimulation reported better stimulation targeting in their area of pain without extraneous paresthesia than patients receiving traditional SCS (94.5 percent vs. 61.2 percent). Finally it shows reduced paresthesia: After 12 months, more than a third of patients who received DRG stimulation were experiencing greater than 80 percent pain relief with no paresthesia. St. Jude Medical submitted their premarket approval submission to the FDA for approval of DRG stimulation in Q1 2015.
Related news and insights
Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), announced that Health Canada has approved Ferriprox (deferiprone) for the treatment of iron overload in patients with sickle cell disease (SCD) or other anemias.
The Menarini Group and Radius Health announced positive topline results from the phase III EMERALD study evaluating RAD 1901 (elacestrant) as a monotherapy versus the standard of care (SoC) for the treatment of ER+/HER2- advanced or metastatic breast cancer (mBC).
Gilead Sciences, Inc. announced the FDA approved a new low-dose tablet dosage form of Biktarvy (bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg tablets) for pediatric patients weighing at least 14 kg to less than 25 kg who are virologically suppressed or new to antiretroviral therapy.